Multimodality imaging in diabetic heart disease

Current Problems in Cardiology

Volumn 36, Issue 1, 2011, Pages 9-47

  Ng, Arnold C T ^a   Delgado, Victoria ^a   Djaberi, Roxanna ^a   Schuijf, Joanne D ^a   Boogers, Mark J ^a   Auger, Dominique ^a   Bertini, Matteo ^a   de Roos, Albert ^a   van der Meer, Rutger W ^a   Lamb, Hildo J ^a   Bax, Jeroen J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; 3 HYDROXYEPHEDRINE C 11; FATTY ACID; RADIOISOTOPE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANGIOCARDIOGRAPHY; ARTICLE; BRACHIAL ARTERY; CARDIAC AUTONOMIC NEUROPATHY; CONTRAST ECHOCARDIOGRAPHY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY CALCIUM SCORING; CORONARY ARTERY DILATATION; DIABETIC CARDIOMYOPATHY; DIASTOLIC BLOOD PRESSURE; DIFFERENTIAL DIAGNOSIS; ECHOCARDIOGRAPHIC INTEGRATED BACKSCATTER; ECHOCARDIOGRAPHY; ENDOTHELIAL DYSFUNCTION; FATTY ACID METABOLISM; HEART FUNCTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE FIBROSIS; HUMAN; MICROANGIOPATHY; MYOCARDIAL PERFUSION IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGICAL ANATOMY; POSITRON EMISSION TOMOGRAPHY; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE ANALYSIS; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SYSTOLIC BLOOD PRESSURE;

CARDIAC IMAGING TECHNIQUES; DIABETIC CARDIOMYOPATHIES; HUMANS;

EID: 78649924574     PISSN: 01462806     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpcardiol.2010.10.001     Document Type: Article

References (120)

1. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation 2006, World Health Organization, World Health Organization, Geneva.
2. Wild S., Roglic G., Green A., et al. Global prevalence of diabetes. Diabetes Care 2004, 27:1047-1053.
3. Kannel W.B., McGee D.L. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979, 241:2035-2038.
4. From A.M., Scott C.G., Chen H.H. The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction: A population-Based Study. J Am Coll Cardiol 2010, 55:300-305.
5. Coughlin S.S., Pearle D.L., Baughman K.L., et al. Diabetes mellitus and risk of idiopathic dilated cardiomyopathy. The Washington, DC Dilated Cardiomyopathy Study. Ann Epidemiol 1994, 4:67-74.
6. Redfield M.M., Jacobsen S.J., Burnett J.C., et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003, 289:194-202.
7. Nichols G.A., Gullion C.M., Koro C.E., et al. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 2004, 27:1879-1884.
8. Rubler S., Dlugash J., Yuceoglu Y.Z., et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972, 30:595-602.
9. Boudina S., Abel E.D. Diabetic cardiomyopathy revisited. Circulation 2007, 115:3213-3223.
10. Marwick T. The diabetic myocardium. Curr Diab Rep 2006, 6:36-41.
11. Lindsey J.B., Marso S.P. Steatosis and diastolic dysfunction: the skinny on myocardial fat. J Am Coll Cardiol 2008, 52:1800-1802.
12. Schaffer J.E. Lipotoxicity: when tissues overeat. Curr Opin Lipidol 2003, 14:281-287.
13. McGavock J.M., Victor R.G., Unger R.H., et al. Adiposity of the heart, revisited. Ann Intern Med 2006, 144:517-524.
14. Lopaschuk G.D., Ussher J.R., Folmes C.D., et al. Myocardial fatty acid metabolism in health and disease. Physiol Rev 2010, 90:207-258.
15. Unger R.H. Lipotoxic diseases. Annu Rev Med 2002, 53:319.
16. Szczepaniak L.S., Dobbins R.L., Metzger G.J., et al. Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn Reson Med 2003, 49:417-423.
17. van der Meer R.W., Doornbos J., Kozerke S., et al. Metabolic imaging of myocardial triglyceride content: reproducibility of 1H MR spectroscopy with respiratory navigator gating in volunteers. Radiology 2007, 245:251-257.
18. Hammer S., Snel M., Lamb H.J., et al. Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases myocardial triglyceride content and improves myocardial function. J Am Coll Cardiol 2008, 52:1006-1012.
19. Iozzo P., Lautamaki R., Borra R., et al. Contribution of glucose tolerance and gender to cardiac adiposity. J Clin Endocrinol Metab 2009, 94:4472-4482.
20. Rijzewijk L.J., van der Meer R.W., Smit J.W.A., et al. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol 2008, 52:1793-1799.
21. van der Meer R.W., Rijzewijk L.J., Diamant M., et al. The ageing male heart: myocardial triglyceride content as independent predictor of diastolic function. Eur Heart J 2008, 29:1516-1522.
22. van der Meer R.W., Rijzewijk L.J., de Jong H.W.A.M., et al. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. Circulation 2009, 119:2069-2077.
23. McGavock J.M., Lingvay I., Zib I., et al. Cardiac steatosis in diabetes mellitus: A 1H-Magnetic Resonance Spectroscopy Study. Circulation 2007, 116:1170-1175.
24. Sharma S., Adrogue J.V., Golfman L., et al. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J 2004, 18:1692-1700.
25. Zhou Y.T., Grayburn P., Karim A., et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci USA 2000, 97:1784-1789.
26. Schrauwen-Hinderling V.B., Hesselink M.K., Meex R., et al. Improved ejection fraction after exercise training in obesity is accompanied by reduced cardiac lipid content. J Clin Endocrinol Metab 2010, 95:1932-1938.
27. Zib I., Jacob A.N., Lingvay I., et al. Effect of pioglitazone therapy on myocardial and hepatic steatosis in insulin-treated patients with type 2 diabetes. J Investig Med 2007, 55:230-236.
28. Kinlay S., Libby P., Ganz P. Endothelial function and coronary artery disease. Curr Opin Lipidol 2001, 12:383-389.
29. Radomski M.W., Palmer R.M., Moncada S. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun 1987, 148:1482-1489.
30. Kubes P., Suzuki M., Granger D.N. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991, 88:4651-4655.
31. Sarkar R., Meinberg E.G., Stanley J.C., et al. Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells. Circ Res 1996, 78:225-230.
32. Creager M.A., Luscher T.F., Cosentino F., et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy. Part I. Circulation 2003, 108:1527-1532.
33. Tan K.C., Chow W.S., Ai V.H., et al. Advanced glycation end products and endothelial dysfunction in type 2 diabetes. Diabetes Care 2002, 25:1055-1059.
34. McDaid E.A., Monaghan B., Parker A.I., et al. Peripheral autonomic impairment in patients newly diagnosed with type II diabetes. Diabetes Care 1994, 17:1422-1427.
35. Celermajer D.S., Sorensen K.E., Gooch V.M., et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992, 340:1111-1115.
36. Anderson T.J., Uehata A., Gerhard M.D., et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995, 26:1235-1241.
37. Deanfield J.E., Halcox J.P., Rabelink T.J. Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007, 115:1285-1295.
38. Bots M.L., Westerink J., Rabelink T.J., et al. Assessment of flow-mediated vasodilatation (FMD) of the brachial artery: effects of technical aspects of the FMD measurement on the FMD response. Eur Heart J 2005, 26:363-368.
39. Kang X., Berman D.S., Lewin H., et al. Comparative ability of myocardial perfusion single-photon emission computed tomography to detect coronary artery disease in patients with and without diabetes mellitus. Am Heart J 1999, 137:949-957.
40. Djaberi R., Roodt J., Schuijf J.D., et al. Endothelial dysfunction in diabetic patients with abnormal myocardial perfusion in the absence of epicardial obstructive coronary artery disease. J Nucl Med 2009, 50:1980-1986.
41. Fang Z.Y., Najos-Valencia O., Leano R., et al. Patients with early diabetic heart disease demonstrate a normal myocardial response to dobutamine. J Am Coll Cardiol 2003, 42:446-453.
42. Moir S., Hanekom L., Fang Z.Y., et al. Relationship between myocardial perfusion and dysfunction in diabetic cardiomyopathy: a study of quantitative contrast echocardiography and strain rate imaging. Heart 2006, 92:1414-1419.
43. Wei K., Ragosta M., Thorpe J., et al. Noninvasive quantification of coronary blood flow reserve in humans using myocardial contrast echocardiography. Circulation 2001, 103:2560-2565.
44. Hansen C.L., Goldstein R.A., Akinboboye O.O., et al. Myocardial perfusion and function: single photon emission computed tomography. J Nucl Cardiol 2007, 14:e39-e60.
45. Amanullah A.M., Berman D.S., Hachamovitch R., et al. Identification of severe or extensive coronary artery disease in women by adenosine technetium-99m sestamibi SPECT. Am J Cardiol 1997, 80:132-137.
46. Hasdai D., Gibbons R.J., Holmes D.R., et al. Coronary endothelial dysfunction in humans is associated with myocardial perfusion defects. Circulation 1997, 96:3390-3395.
47. Wackers F.J., Young L.H., Inzucchi S.E., et al. Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. Diabetes Care 2004, 27:1954-1961.
48. Valensi P., Paries J., Brulport-Cerisier V., et al. Predictive value of silent myocardial ischemia for cardiac events in diabetic patients: influence of age in a French multicenter study. Diabetes Care 2005, 28:2722-2727.
49. Zellweger M.J., Hachamovitch R., Kang X., et al. Prognostic relevance of symptoms versus objective evidence of coronary artery disease in diabetic patients. Eur Heart J 2004, 25:543-550.
50. Kang X., Berman D.S., Lewin H.C., et al. Incremental prognostic value of myocardial perfusion single photon emission computed tomography in patients with diabetes mellitus. Am Heart J 1999, 138:1025-1032.
51. Pancholy S.B., Fattah A.A., Kamal A.M., et al. Independent and incremental prognostic value of exercise thallium single-photon emission computed tomographic imaging in women. J Nucl Cardiol 1995, 2:110-116.
52. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993, 362:801-809.
53. Egashira K., Hirooka Y., Kai H., et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994, 89:2519-2524.
54. Wackers F.J., Chyun D.A., Young L.H., et al. Resolution of asymptomatic myocardial ischemia in patients with type 2 diabetes in the detection of ischemia in asymptomatic diabetics (DIAD) study. Diabetes Care 2007, 30:2892-2898.
55. Bateman T.M., Heller G.V., McGhie A.I., et al. Diagnostic accuracy of rest/stress ECG-gated Rb-82 myocardial perfusion PET: comparison with ECG-gated Tc-99m sestamibi SPECT. J Nucl Cardiol 2006, 13:24-33.
56. Bengel F.M., Higuchi T., Javadi M.S., et al. Cardiac positron emission tomography. J Am Coll Cardiol 2009, 54:1-15.
57. Bergmann S.R., Herrero P., Markham J., et al. Noninvasive quantitation of myocardial blood flow in human subjects with oxygen-15-labeled water and positron emission tomography. J Am Coll Cardiol 1989, 14:639-652.
58. Lortie M., Beanlands R.S., Yoshinaga K., et al. Quantification of myocardial blood flow with 82Rb dynamic PET imaging. Eur J Nucl Med Mol Imaging 2007, 34:1765-1774.
59. Kaufmann P.A., Gnecchi-Ruscone T., Yap J.T., et al. Assessment of the reproducibility of baseline and hyperemic myocardial blood flow measurements with 15O-labeled water and PET. J Nucl Med 1999, 40:1848-1856.
60. Campisi R., Czernin J., Schoder H., et al. Effects of long-term smoking on myocardial blood flow, coronary vasomotion, and vasodilator capacity. Circulation 1998, 98:119-125.
61. Pitkanen O.P., Raitakari O.T., Niinikoski H., et al. Coronary flow reserve is impaired in young men with familial hypercholesterolemia. J Am Coll Cardiol 1996, 28:1705-1711.
62. Kjaer A., Meyer C., Nielsen F.S., et al. Dipyridamole, cold pressor test, and demonstration of endothelial dysfunction: a PET study of myocardial perfusion in diabetes. J Nucl Med 2003, 44:19-23.
63. Momose M., Abletshauser C., Neverve J., et al. Dysregulation of coronary microvascular reactivity in asymptomatic patients with type 2 diabetes mellitus. Eur J Nucl Med Mol Imaging 2002, 29:1675-1679.
64. Prior J.O., Quinones M.J., Hernandez-Pampaloni M., et al. Coronary circulatory dysfunction in insulin resistance, impaired glucose tolerance, and type 2 diabetes mellitus. Circulation 2005, 111:2291-2298.
65. Taskiran M., Fritz-Hansen T., Rasmussen V., et al. Decreased myocardial perfusion reserve in diabetic autonomic neuropathy. Diabetes 2002, 51:3306-3310.
66. Vinik A.I., Freeman R., Erbas T. Diabetic autonomic neuropathy. Semin Neurol 2003, 23:365-372.
67. Boulton A.J., Vinik A.I., Arezzo J.C., et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005, 28:956-962.
68. Nagamachi S., Fujita S., Nishii R., et al. Prognostic value of cardiac I-123 metaiodobenzylguanidine imaging in patients with non-insulin-dependent diabetes mellitus. J Nucl Cardiol 2006, 13:34-42.
69. Vinik A.I., Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation 2007, 115:387-397.
70. Vinik A.I., Maser R.E., Mitchell B.D., et al. Diabetic autonomic neuropathy. Diabetes Care 2003, 26:1553-1579.
71. Ziegler D., Weise F., Langen K.J., et al. Effect of glycaemic control on myocardial sympathetic innervation assessed by [123I]metaiodobenzylguanidine scintigraphy: a 4-year prospective study in IDDM patients. Diabetologia 1998, 41:443-451.
72. Stevens M.J., Raffel D.M., Allman K.C., et al. Cardiac sympathetic dysinnervation in diabetes: implications for enhanced cardiovascular risk. Circulation 1998, 98:961-968.
73. Patel A.D., Iskandrian A.E. MIBG imaging. J Nucl Cardiol 2002, 9:75-94.
74. Allman K.C., Stevens M.J., Wieland D.M., et al. Noninvasive assessment of cardiac diabetic neuropathy by carbon-11 hydroxyephedrine and positron emission tomography. J Am Coll Cardiol 1993, 22:1425-1432.
75. Nagamachi S., Jinnouchi S., Kurose T., et al. Serial change in 123I-MIBG myocardial scintigraphy in non-insulin-dependent diabetes mellitus. Ann Nucl Med 2002, 16:33-38.
76. Verberne H.J., Brewster L.M., Somsen G.A., et al. Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur Heart J 2008, 29:1147-1159.
77. Turpeinen A.K., Vanninen E., Kuikka J.T., et al. Demonstration of regional sympathetic denervation of the heart in diabetes. Comparison between patients with NIDDM and IDDM. Diabetes Care 1996, 19:1083-1090.
78. Goraya T.Y., Leibson C.L., Palumbo P.J., et al. Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study. J Am Coll Cardiol 2002, 40:946-953.
79. Pundziute G., Schuijf J.D., Jukema J.W., et al. Prognostic value of multislice computed tomography coronary angiography in patients with known or suspected coronary artery disease. J Am Coll Cardiol 2007, 49:62-70.
80. Ambrose J.A., Tannenbaum M.A., Alexopoulos D., et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol 1988, 12:56-62.
81. Little W.C., Constantinescu M., Applegate R.J., et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease?. Circulation 1988, 78:1157-1166.
82. Sarwar A., Shaw L.J., Shapiro M.D., et al. Diagnostic and prognostic value of absence of coronary artery calcification. J Am Coll Cardiol Imaging 2009, 2:675-688.
83. Budoff M.J., Shaw L.J., Liu S.T., et al. Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. J Am Coll Cardiol 2007, 49:1860-1870.
84. Raggi P., Shaw L.J., Berman D.S., et al. Prognostic value of coronary artery calcium screening in subjects with and without diabetes. J Am Coll Cardiol 2004, 43:1663-1669.
85. Anand D.V., Lim E., Hopkins D., et al. Risk stratification in uncomplicated type 2 diabetes: prospective evaluation of the combined use of coronary artery calcium imaging and selective myocardial perfusion scintigraphy. Eur Heart J 2006, 27:713-721.
86. Burgstahler C., Beck T., Reimann A., et al. Diagnostic accuracy of multislice computed tomography for the detection of coronary artery disease in diabetic patients. J Diabetes Complications 2007, 21:69-74.
87. Schuijf J.D., Bax J.J., Jukema J.W., et al. Noninvasive angiography and assessment of left ventricular function using multislice computed tomography in patients with type 2 diabetes. Diabetes Care 2004, 27:2905-2910.
88. Pundziute G., Schuijf J.D., Jukema J.W., et al. Noninvasive assessment of plaque characteristics with multislice computed tomography coronary angiography in symptomatic diabetic patients. Diabetes Care 2007, 30:1113-1119.
89. Pundziute G., Schuijf J.D., Jukema J.W., et al. Type 2 diabetes is associated with more advanced coronary atherosclerosis on multislice computed tomography and virtual histology intravascular ultrasound. J Nucl Cardiol 2009, 16:376-383.
90. Scholte A.J., Schuijf J.D., Kharagjitsingh A.V., et al. Prevalence of coronary artery disease and plaque morphology assessed by multi-slice computed tomography coronary angiography and calcium scoring in asymptomatic patients with type 2 diabetes. Heart 2008, 94:290-295.
91. van Werkhoven J.M., Cademartiri F., Seitun S., et al. Prognostic value of computed tomographic coronary angiography in patients with diabetes: comparison with a non-diabetic population. Radiology 2010, 256:83-92.
92. Kawaguchi M., Techigawara M., Ishihata T., et al. A comparison of ultrastructural changes on endomyocardial biopsy specimens obtained from patients with diabetes mellitus with and without hypertension. Heart Vessels 1997, 12:267-274.
93. Adeghate E. Molecular and cellular basis of the aetiology and management of diabetic cardiomyopathy: a short review. Mol Cell Biochem 2004, 261:187-191.
94. Loganathan R., Bilgen M., Al Hafez B., et al. Characterization of alterations in diabetic myocardial tissue using high resolution MRI. Int J Cardiovasc Imaging 2006, 22:81-90.
95. Picano E., Pelosi G., Marzilli M., et al. In vivo quantitative ultrasonic evaluation of myocardial fibrosis in humans. Circulation 1990, 81:58-64.
96. Di Bello V., Talarico L., Picano E., et al. Increased echodensity of myocardial wall in the diabetic heart: an ultrasound tissue characterization study. J Am Coll Cardiol 1995, 25:1408-1415.
97. Fang Z.Y., Yuda S., Anderson V., et al. Echocardiographic detection of early diabetic myocardial disease. J Am Coll Cardiol 2003, 41:611-617.
98. Regan T.J., Wu C.F., Yeh C.K., et al. Myocardial composition and function in diabetes. The effects of chronic insulin use. Circ Res 1981, 49:1268-1277.
99. Bhimji S., Godin D.V., McNeill J.H. Biochemical and functional changes in hearts from rabbits with diabetes. Diabetologia 1985, 28:452-457.
100. Kim R.J., Fieno D.S., Parrish T.B., et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 1999, 100:1992-2002.
101. Kwong R.Y., Sattar H., Wu H., et al. Incidence and prognostic implication of unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction. Circulation 2008, 118:1011-1020.
102. Aneja A., Tang W.H., Bansilal S., et al. Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med 2008, 121:748-757.
103. Nagueh S.F., Appleton C.P., Gillebert T.C., et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009, 22:107-133.
104. Nagueh S.F., Middleton K.J., Kopelen H.A., et al. Tissue imaging: A noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 1997, 30:1527-1533.
105. Nagueh S.F., Sun H., Kopelen H.A., et al. Hemodynamic determinants of the mitral annulus diastolic velocities by tissue Doppler. J Am Coll Cardiol 2001, 37:278-285.
106. Leung D.Y., Ng A.C. Emerging clinical role of strain imaging in echocardiography. Heart Lung Circ 2010, 19:161-174.
107. Marwick T.H. Measurement of strain and strain rate by echocardiography: ready for prime time?. J Am Coll Cardiol 2006, 47:1313-1327.
108. Ng A.C.T., Tran D.T., Newman M., et al. Comparison of myocardial tissue velocities measured by two-dimensional speckle tracking and tissue Doppler imaging. Am J Cardiol 2008, 102:784-789.
109. Ng A.C.T., Delgado V., Bertini M., et al. Findings from left ventricular strain and strain rate imaging in asymptomatic patients with type 2 diabetes mellitus. Am J Cardiol 2009, 104:1398-1401.
110. van Dalen B.M., Bosch J.G., Kauer F., et al. Assessment of mitral annular velocities by speckle tracking echocardiography versus tissue Doppler imaging: validation, feasibility, and reproducibility. J Am Soc Echocardiogr 2009, 22:1302-1308.
111. Zabalgoitia M., Ismaeil M.F., Anderson L., et al. Prevalence of diastolic dysfunction in normotensive, asymptomatic patients with well-controlled type 2 diabetes mellitus. Am J Cardiol 2001, 87:320-323.
112. Boyer J.K., Thanigaraj S., Schechtman K.B., et al. Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am J Cardiol 2004, 93:870-875.
113. Fang Z.Y., Leano R., Marwick T.H. Relationship between longitudinal and radial contractility in subclinical diabetic heart disease. Clin Sci 2004, 106:53-60.
114. Fang Z.Y., Schull-Meade R., Downey M., et al. Determinants of subclinical diabetic heart disease. Diabetologia 2005, 48:394-402.
115. Gulati V., Katz W., Follansbee W., et al. Mitral annular descent velocity by tissue Doppler echocardiography as an index of global left ventricular function. Am J Cardiol 1996, 77:979-984.
116. Delgado V., Mollema S.A., Ypenburg C., et al. Relation between global left ventricular longitudinal strain assessed with novel automated function imaging and biplane left ventricular ejection fraction in patients with coronary artery disease. J Am Soc Echocardiogr 2008, 21:1244-1250.
117. Greenberg N.L., Firstenberg M.S., Castro P.L., et al. Doppler-derived myocardial systolic strain rate is a Strong Index of Left Ventricular Contractility. Circulation 2002, 105:99-105.
118. Vinereanu D., Nicolaides E., Tweddel A.C., et al. Subclinical left ventricular dysfunction in asymptomatic patients with type II diabetes mellitus, related to serum lipids and glycated haemoglobin. Clin Sci 2003, 105:591-599.
119. Galderisi M., de Simone G., Innelli P., et al. Impaired inotropic response in type 2 diabetes mellitus: a Strain Rate Imaging Study. Am J Hypertens 2007, 20:548-555.
120. Greenbaum R.A., Ho S.Y., Gibson D.G., et al. Left ventricular fibre architecture in man. Br Heart J 1981, 45:248-263.